Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-08-04 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Investor Presentation 18 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated August 5, 2021, about a strategic research partnership between Imugene Limited and Celularity Inc. It includes company histories, product pipelines, clinical milestones, and scientific rationale for therapies. The content is structured as a presentation with disclaimers, company background, partnership highlights, and detailed scientific and clinical information. There is no indication that this is a regulatory filing, earnings release, or formal report such as an annual or interim report. The document is clearly designed to inform investors and stakeholders about the partnership and the companies' strategic directions, which fits the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2021-08-04 English
Imugene Investor Webinar with Celularity Dr Robert Hariri 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about an upcoming investor webinar involving Imugene Limited and Celularity's CEO. It includes details on how to register for the webinar and mentions that a recording will be available after the session. There is no financial data, no report attached or published, and no detailed presentation content included. The document is short (3063 characters) and serves as an announcement of an event rather than the event content or a report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2021-08-04 English
Application for quotation of securities - IMU 7 pages 28.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities by Imugene Limited, detailing the number and type of securities to be quoted on the ASX, issue dates, and related issuance details. It references Appendix 3B filings and provides distribution schedules and issued capital information. There are no financial statements, management discussion, or earnings data present. The document is a formal announcement related to capital market activities, specifically the quotation of securities, which aligns with announcements about share issues or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing fallback.
2021-08-03 English
Notice Under Section 708A 1 page 159.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 04 August 2021, providing a notice under section 708A(5) of the Corporations Act 2001. It details the issuance of 300,000,000 ordinary shares at $0.30 each without disclosure to investors under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant provisions and absence of excluded information. This is a formal announcement regarding a share issue, specifically a capital raising event. The document is short (1311 characters) and is a regulatory notice about share issuance, not a full financial report or detailed presentation. Therefore, it fits the category of Capital/Financing Update (CAP).
2021-08-03 English
Imugene to present at NWR virtual investor conference 1
Regulatory Filings Classification · 90% confidence The document is an ASX announcement about Imugene Limited's Managing Director & CEO presenting at the NWR Virtual Investor Conference. It includes details about the event, registration links, and company background information. There is no financial data, no report attached or referenced as being published, and no detailed presentation content included. The document is essentially an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Given the short length (2978 characters) and the nature of the content, this fits best as an Investor Presentation announcement. However, since the actual presentation content is not included, and it is an announcement of the event, the best classification is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2021-08-01 English
Imugene completes $90 M placement and launches $5 M SPP 4 pages 176.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing a $90 million placement and a $5 million share purchase plan (SPP) by Imugene Limited. It discusses the terms of the placement, the SPP, the issuance of new shares and options, key dates, and the use of proceeds. The content focuses on fundraising activities and capital structure changes, including share issuance and options. There are no financial statements or detailed financial performance data presented, nor is this a report or transcript. The document is clearly an update on capital raising activities and financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-07-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.